Caseware UK (AP4) 2024.0.164 2024.0.164 2024-06-302024-06-304true2024-05-30falsefalseThe company is dormant and has not traded during the periodtrue 15750921 2024-05-29 15750921 2024-05-30 2024-06-30 15750921 2023-05-30 2024-05-29 15750921 2024-06-30 15750921 c:Director3 2024-05-30 2024-06-30 15750921 d:CurrentFinancialInstruments 2024-06-30 15750921 d:ShareCapital 2024-06-30 15750921 c:OrdinaryShareClass1 2024-05-30 2024-06-30 15750921 c:OrdinaryShareClass1 2024-06-30 15750921 c:EntityHasNeverTraded 2024-05-30 2024-06-30 15750921 c:FRS102 2024-05-30 2024-06-30 15750921 c:AuditExempt-NoAccountantsReport 2024-05-30 2024-06-30 15750921 c:FullAccounts 2024-05-30 2024-06-30 15750921 c:PrivateLimitedCompanyLtd 2024-05-30 2024-06-30 15750921 e:PoundSterling 2024-05-30 2024-06-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 15750921









PROGNOSIS BIOTECH LTD


UNAUDITED

FINANCIAL STATEMENTS

FOR THE PERIOD FROM 30 MAY 2024 TO 30 JUNE 2024

 
PROGNOSIS BIOTECH LTD
 

CONTENTS



Page
Balance sheet
 
1
Notes to the financial statements
 
2 - 3


 
PROGNOSIS BIOTECH LTD
REGISTERED NUMBER:15750921

BALANCE SHEET
AS AT 30 JUNE 2024

2024
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
  
250,000

  
250,000

Total assets less current liabilities
  
 
 
250,000

  

Net assets
  
250,000


Capital and reserves
  

Called up share capital 
  
250,000

  
250,000


For the period ended 30 June 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 4 December 2025.




A Ntantasios
Director

The notes on pages 2 to 3 form part of these financial statements.

1

 
PROGNOSIS BIOTECH LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024

1.


General information

ProGnosis Biotech Ltd is a private company, limited by shares, registered in England and Wales, registration number 15750921. The registered office address is Elsley Court, 20-22 Great Titchfield Street, London, W1W 8BE.

The company was incorporated on 30 May 2024.

The company is dormant and has not traded during the period.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The company's functional and presentational currency is pound sterling.

The following principal accounting polices have been applied.
 

 
2.2

Debtors

Short-term debtors are measured at transaction price, less any impairment. 


3.


Employees

The average monthly number of employees, including directors, during the period was 4.


4.


Debtors

2024
£


Amounts owed by group undertakings
250,000



5.


Share capital

2024
£
Allotted, called up and fully paid


25,000 Ordinary shares of £10.00 each
250,000



25,000 ordinary shares of £10 each were issued on incorporation at an aggregate nominal value of £250,000.

2

 
PROGNOSIS BIOTECH LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024

6.


Related party transactions

No disclosure has been made of transactions with other wholly owned group companies in accordance with FRS 102 Section 1A paragraph 1AC.35.

3